Riverhead Capital Management LLC trimmed its stake in Eli Lilly And Co (NYSE:LLY) by 3.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 31,617 shares of the company’s stock after selling 1,114 shares during the quarter. Riverhead Capital Management LLC’s holdings in Eli Lilly And Co were worth $3,393,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in LLY. Migdal Insurance & Financial Holdings Ltd. grew its stake in Eli Lilly And Co by 3,062.5% during the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,783 shares of the company’s stock worth $237,000 after buying an additional 2,695 shares during the period. Smith Asset Management Group LP acquired a new position in shares of Eli Lilly And Co during the second quarter worth $65,407,000. Rice Hall James & Associates LLC acquired a new position in shares of Eli Lilly And Co during the second quarter worth $212,000. Victory Capital Management Inc. lifted its position in shares of Eli Lilly And Co by 5.6% during the second quarter. Victory Capital Management Inc. now owns 20,797 shares of the company’s stock worth $1,775,000 after purchasing an additional 1,104 shares in the last quarter. Finally, Global Financial Private Capital LLC lifted its position in shares of Eli Lilly And Co by 87.6% during the second quarter. Global Financial Private Capital LLC now owns 6,714 shares of the company’s stock worth $573,000 after purchasing an additional 3,135 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.
LLY stock opened at $113.58 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $119.84. The firm has a market cap of $122.71 billion, a price-to-earnings ratio of 26.54, a price-to-earnings-growth ratio of 1.81 and a beta of 0.31.
Eli Lilly And Co (NYSE:LLY) last released its earnings results on Tuesday, November 6th. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a net margin of 1.85% and a return on equity of 42.84%. The firm had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The firm’s revenue for the quarter was up 7.1% compared to the same quarter last year. Equities research analysts predict that Eli Lilly And Co will post 5.58 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 10th. Shareholders of record on Thursday, November 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, November 14th. This represents a $2.25 annualized dividend and a yield of 1.98%. Eli Lilly And Co’s payout ratio is 52.57%.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 15,500 shares of the business’s stock in a transaction on Tuesday, December 4th. The shares were sold at an average price of $119.00, for a total transaction of $1,844,500.00. Following the completion of the sale, the insider now owns 118,015,304 shares in the company, valued at $14,043,821,176. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Eli & Co Lilly sold 10,059 shares of the business’s stock in a transaction on Wednesday, September 12th. The shares were sold at an average price of $14.83, for a total transaction of $149,174.97. Following the sale, the insider now owns 3,894,318 shares of the company’s stock, valued at approximately $57,752,735.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,962,800 shares of company stock valued at $149,601,553. 0.11% of the stock is owned by insiders.
A number of research firms have recently commented on LLY. Citigroup cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research report on Monday, November 26th. Credit Suisse Group raised shares of Eli Lilly And Co from an “underperform” rating to a “neutral” rating in a report on Wednesday, October 31st. ValuEngine cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, November 6th. JPMorgan Chase & Co. set a $123.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Friday, October 5th. Finally, Cantor Fitzgerald set a $110.00 price target on shares of Eli Lilly And Co and gave the company a “buy” rating in a report on Thursday, September 27th. Nine research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $111.53.
ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Position Cut by Riverhead Capital Management LLC” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/eli-lilly-and-co-lly-position-cut-by-riverhead-capital-management-llc.html.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: What factors cause inflation to rise?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.